Frank Tufaro
Chief Executive Officer at DNAtrix, Inc.
Net worth: 33 064 $ as of 2024-04-29
Frank Tufaro active positions
Companies | Position | Start | End |
---|---|---|---|
Protocol Intelligence, Inc.
Protocol Intelligence, Inc. Packaged SoftwareTechnology Services Protocol Intelligence, Inc. is an American company that is developing an intelligent navigational system for myeloma oncologists. The system includes software, human data curation, and decision support that advises physicians on which drugs to use and when to use them, optimized for each patient's evolving needs and physician-imposed constraints. | Director/Board Member | - | - |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Director/Board Member | - | - |
Chief Executive Officer | - | - |
Career history of Frank Tufaro
Former positions of Frank Tufaro
Companies | Position | Start | End |
---|---|---|---|
THERIVA BIOLOGICS, INC. | Chief Operating Officer | 2022-03-21 | 2023-05-09 |
Opa Therapeutics, Inc. | President | 2020-04-30 | 2022-02-28 |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Director/Board Member | 2011-05-29 | 2019-11-30 |
Chief Executive Officer | 2011-05-29 | 2019-11-30 | |
President | 2009-12-31 | 2019-11-30 | |
University of British Columbia | Corporate Officer/Principal | 1986-12-31 | 2001-12-31 |
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Chief Operating Officer | - | - |
Nurel Therapeutics, Inc.
Nurel Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nurel Therapeutics, Inc. was a biotechnology company. The company develops products to treat and manage pain and peripheral nerve damage and also develops products to vascular diseases. The company's products use a proprietary drug delivery technology derived from an 'inert' herpes simplex virus that provides gene based medicine. The company was headquartered in Pittsburgh, PA. | Chief Executive Officer | - | - |
Founder | - | - | |
President | - | - | |
NeuroVir Therapeutic, Inc.
NeuroVir Therapeutic, Inc. Pharmaceuticals: MajorHealth Technology Part of MediGene AG, NeuroVir Therapeutic, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company is based in San Diego, CA. The company was founded by Michael R. Hayden, Frank Tufaro. NeuroVir Therapeutic was acquired by MediGene AG on January 12, 2001 for $53 million. | Chief Executive Officer | - | - |
Founder | - | - | |
░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░ | - | - | |
░░░░░░░░░ | - | - |
Training of Frank Tufaro
McGill University | Doctorate Degree |
Statistics
International
United States | 9 |
Canada | 3 |
Spain | 2 |
Operational
Chief Executive Officer | 5 |
President | 4 |
Director/Board Member | 3 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Retail Trade | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
THERIVA BIOLOGICS, INC. | Health Technology |
Private companies | 8 |
---|---|
Allera Health Products, Inc.
Allera Health Products, Inc. Specialty StoresRetail Trade Allera Health Products, Inc. provides healthcare products. It develops supplements that enhance immune system and drugs that fight illness and diseases. Its products include ProLigna and ImmunExtra. The company was founded in 2005 and is headquartered in St. Petersburg, FL. | Retail Trade |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Electronic Technology |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
NeuroVir Therapeutic, Inc.
NeuroVir Therapeutic, Inc. Pharmaceuticals: MajorHealth Technology Part of MediGene AG, NeuroVir Therapeutic, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company is based in San Diego, CA. The company was founded by Michael R. Hayden, Frank Tufaro. NeuroVir Therapeutic was acquired by MediGene AG on January 12, 2001 for $53 million. | Health Technology |
Nurel Therapeutics, Inc.
Nurel Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nurel Therapeutics, Inc. was a biotechnology company. The company develops products to treat and manage pain and peripheral nerve damage and also develops products to vascular diseases. The company's products use a proprietary drug delivery technology derived from an 'inert' herpes simplex virus that provides gene based medicine. The company was headquartered in Pittsburgh, PA. | Health Technology |
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Commercial Services |
Opa Therapeutics, Inc. | |
Protocol Intelligence, Inc.
Protocol Intelligence, Inc. Packaged SoftwareTechnology Services Protocol Intelligence, Inc. is an American company that is developing an intelligent navigational system for myeloma oncologists. The system includes software, human data curation, and decision support that advises physicians on which drugs to use and when to use them, optimized for each patient's evolving needs and physician-imposed constraints. | Technology Services |
- Stock Market
- Insiders
- Frank Tufaro
- Experience